a public good project by the
Synthesis
Company
of California

© 2026

M. Rother | doi.page

0 works0 citations0 h-index

M. Rother

AlzeCure Pharma (Sweden)(SE)

Publications by Year

Research Areas

Inflammatory mediators and NSAID effects, Heart Rate Variability and Autonomic Control, Osteoarthritis Treatment and Mechanisms, EEG and Brain-Computer Interfaces, Neonatal and fetal brain pathology

Most-Cited Works

→ Efficacy and safety of epicutaneous ketoprofen in Transfersome (IDEA-033) versus oral celecoxib and placebo in osteoarthritis of the knee: multicentre randomised controlled trial(2007)113 cited
→ Propentofylline in the Treatment of Alzheimer’s Disease and Vascular Dementia: A Review of Phase III Trials(1998)93 cited
→ Clinical Trials in Dementia with Propentofyllinea(1997)93 cited
→ A 12-Month, Randomized, Placebo-Controlled Trial of Propentofylline (HWA 285) in Patients with Dementia According to DSM III-R(1997)82 cited
→ Preclinical characterisation of NSAIDs in ultradeformable carriers or conventional topical gels(2008)81 cited
→ Improved risk-benefit ratio for topical triamcinolone acetonide in TransfersomeR in comparison with equipotent cream and ointment: a randomized controlled trial(2003)60 cited

→ A multicentre, randomized, placebo- and active-controlled trial comparing the efficacy and safety of topical ketoprofen in Transfersome gel (IDEA-033) with ketoprofen-free vehicle (TDT 064) and oral celecoxib for knee pain associated with osteoarthritis(2013)

59 cited

→ Occlusion effect on transcutaneous NSAID delivery from conventional and carrier-based formulations(2008)53 cited

Propentofylline in the treatment of vascular dementia and Alzheimer-type dementia: overview of phase I and phase II clinical trials.(1998)

→ Cardiac aliasing — a possible cause for the misinterpretation of cardiorespirographic data in neonates(1989)44 cited